ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04216589 (A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
Who cites it
1 citing paper in PubMed.
- Metformin and Weight Changes in Non-diabetic Older People With HIV (METFORAGING): A Double-Blind, Randomized, Placebo-Controlled, Pilot Trial.Open forum infectious diseases · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundWe previously reported reductions in weight and cardiometabolic risk factors in people with human immunodeficiency virus (PWH) receiving semaglutide; here, we explored the durability of these changes after treatment cessation.
methodsACTG A5371 enrolled PWH ≥18 years on suppressive antiretroviral therapy with metabolic dysfunction-associated steatotic liver disease. All received subcutaneous semaglutide 1 mg weekly for 24 weeks followed by 24 weeks off semaglutide. We measured weight and cardiometabolic risk factors (blood pressure, cholesterol, metabolic syndrome) at weeks 0, 24, and 48. Mean (95% confidence interval [CI]) changes were estimated using linear regression.
resultsThe 49 participants had a median age of 52 years, body mass index 35 kg/m2, 39% Hispanic and 33% Black, and 43% female. After the mean 7.8 kg (95% CI, 6.1-9.5) weight loss in the first 24 weeks, absolute mean weight regain from 24 to 48 weeks was +2.9 kg (95% CI, 1.5-4.3). Weight regain was accompanied by significant increases in waist circumference (2.0 cm [0.9-3.1]) and fasting glucose (5.1 mg/dL [0.9-9.3]) without significant changes in blood pressure, total or low-density lipoprotein cholesterol, triglycerides, or metabolic syndrome.
conclusionsShort-term, low-dose, semaglutide was associated with cardiometabolic benefit in PWH, but rapid weight regain and some loss of cardiometabolic benefit occurred after stopping semaglutide, similar to the general population. Further study of higher dose semaglutide and strategies to maintain benefits following initial therapy are needed in PWH. ClinicalTrials.gov: NCT04216589.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.